Kamada Ltd. (KMDA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $8.42. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of KMDA = $19.68 (+133.7% from the current price, the stock appears undervalued). Analyst consensus target is KMDA = $12 (+42.5% upside).
Valuation: KMDA trades at a trailing Price-to-Earnings (P/E) of 23.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.36.
Financials: revenue is $195M, +14.8%/yr average growth. Net income is $22M, growing at +194.2%/yr. Net profit margin is 11.2% (healthy). Gross margin is 40.1% (+4 pp trend).
Balance sheet: total debt is $12M against $269M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 4.07 (strong liquidity). Debt-to-assets is 3.1%. Total assets: $379M.
Analyst outlook: 5 / 6 analysts rate KMDA as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 90/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 51/100 (Partial), Future 94/100 (Pass), Income 55/100 (Partial).
